InsiderTrades.com logo
Biden replacement revealed?
From Paradigm Press   |   Ad
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
See his shocking evidence in this new report
Tom Frohlich net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Tom Frohlich Biography and Net Worth

COO of Chinook Therapeutics
Tom is chief operating officer at Chinook Therapeutics, overseeing the business development, CMC, quality, new product planning, program management and program team leadership functions. Tom co-founded and joined Chinook in January 2019 as chief business officer. Prior to Chinook, he served as entrepreneur-in-residence at Versant Ventures. From 2014 to 2018, Tom was VP of business development at Arbutus Biopharma, where he played a key role in multiple transactions including a licensing deal with Alexion and the merger of Tekmira/Oncore. Prior to that, Tom spent over 12 years working internationally at J&J and Merck in various roles leading commercial strategy across all stages of product development, including the global launches of telaprevir and Stelara. Tom has a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.

What is Tom Frohlich's net worth?

The estimated net worth of Tom Frohlich is at least $6.09 million as of February 10th, 2023. Mr. Frohlich owns 150,777 shares of Chinook Therapeutics stock worth more than $6,089,883 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. Frohlich may own. Additionally, Mr. Frohlich receives a salary of $627,440.00 as COO at Chinook Therapeutics. Learn More about Tom Frohlich's net worth.

How old is Tom Frohlich?

Mr. Frohlich is currently 47 years old. There are 4 older executives and no younger executives at Chinook Therapeutics. The oldest executive at Chinook Therapeutics is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 63 years old. Learn More on Tom Frohlich's age.

What is Tom Frohlich's salary?

As the COO of Chinook Therapeutics, Inc., Mr. Frohlich earns $627,440.00 per year. There are 2 executives that earn more than Mr. Frohlich. The highest earning executive at Chinook Therapeutics is Mr. Eric L. Dobmeier J.D., Pres, CEO & Director, who commands a salary of $972,190.00 per year. Learn More on Tom Frohlich's salary.

How do I contact Tom Frohlich?

The corporate mailing address for Mr. Frohlich and other Chinook Therapeutics executives is 740 HEINZ AVENUE, BERKELEY CA, 94710. Chinook Therapeutics can also be reached via phone at (206) 485-7241 and via email at [email protected]. Learn More on Tom Frohlich's contact information.

Has Tom Frohlich been buying or selling shares of Chinook Therapeutics?

Tom Frohlich has not been actively trading shares of Chinook Therapeutics in the last ninety days. Most recently, Tom Frohlich sold 3,700 shares of the business's stock in a transaction on Friday, February 10th. The shares were sold at an average price of $23.75, for a transaction totalling $87,875.00. Following the completion of the sale, the chief operating officer now directly owns 150,777 shares of the company's stock, valued at $3,580,953.75. Learn More on Tom Frohlich's trading history.

Who are Chinook Therapeutics' active insiders?

Chinook Therapeutics' insider roster includes Srinivas Akkaraju (Director), Eric Bjerkholt (CFO), Jerel Davis (Director), Eric Dobmeier (CEO), Tom Frohlich (COO), Alan Glicklich (Insider), and Andrew King (Insider). Learn More on Chinook Therapeutics' active insiders.

Are insiders buying or selling shares of Chinook Therapeutics?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 26,123 shares worth more than $586,102.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company. Learn More about insider trades at Chinook Therapeutics.

Information on this page was last updated on 8/1/2023.

Tom Frohlich Insider Trading History at Chinook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/10/2023Sell3,700$23.75$87,875.00150,777View SEC Filing Icon  
1/31/2023Sell4,566$24.68$112,688.88147,674View SEC Filing Icon  
12/13/2022Sell10,000$25.00$250,000.00143,907View SEC Filing Icon  
11/7/2022Sell10,000$22.16$221,600.00143,907View SEC Filing Icon  
10/6/2022Sell7,360$19.69$144,918.40143,907View SEC Filing Icon  
2/11/2022Sell3,735$12.74$47,583.90View SEC Filing Icon  
11/10/2021Sell6,230$15.48$96,440.40View SEC Filing Icon  
11/8/2021Sell13,770$15.17$208,890.90View SEC Filing Icon  
11/5/2021Sell20,000$14.00$280,000.00View SEC Filing Icon  
9/24/2021Sell20,000$13.00$260,000.00View SEC Filing Icon  
See Full Table

Tom Frohlich Buying and Selling Activity at Chinook Therapeutics

This chart shows Tom Frohlich's buying and selling at Chinook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chinook Therapeutics Company Overview

Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

2 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34
The “Perfect Storm” for Gold
From Gold Safe Exchange   |   Ad
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Click here now to download the free Precious Metals Buying Guide!